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A B ST R A C T
Ovarian hyperstimulation syndrom e (OHSS) is an iatrogenic complication o f controlled ovarian 
hyperstim ulation (COH). Its pathogenesis is not clarified yet. In the recent years a number o f studies focused 
on the vascular endothelial growth factor (VEGF) and antihtrom bin III (AT III) indicators. VEGF is 
homodimeric, heparin-binding glycoprotein, stim ulating vascular permeability. Antithrom bin III is protease 
inhibitor o f activated clotting factors. This study aimed at exam ining the V EG F-A 165 and AT III indicators 
with two OHSS patients. Two methods were used for the determ ination o f the indicators o f VEGF-Aies and 
AT III: ELISA for VEG F and chrom ogenic assay for ATT III. Kits o f R/D Systems and AmericanDiagnostica  
Inc. were used to estimate VEGF and AT III indicators in serum and plasma. There were higher indicators of 
VEGFA 165 (180pg/m l) and reduction o f AT III indicators (48% ) in the patient with a severe form o f  OHSS 
than in the control group while these indicators were normal in the patient with a moderate form o f OHSS. 
Our results confirmed some published data concerning the im portance o f  VEGF and AT III in the genesis o f  
OHSS. This study should include a larger group o f patients in order to follow-up statistically and authentically  
the variations o f the indicators o f both factors and their importance for OHSS.
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The ovarian hyperstimulation syndrome (OHSS) is a seri­
ous and potentially life-threatening physiologic complica­
tion classically encountered in patients who undergo con­
trolled ovarian hyperstimulation cycles (COH). It presents 
with a mild, moderate and severe form, according to 
Golan's classification. The following factors are of 
pathophysiological importance: polycystic ovarian syn­
drome (PCOS) (4); high estradiol levels; elevation o f hu­
man chorion gonadotropin (HCG); activation of the 
prorenin-renin-angiotensin chain (3); increased synthesis of 
prostaglandins (PG), histamine, serotonin, and cytokines 
such as IL; deficiency o f the enzyme 17-20 desmolase; role 
o f inhibins and activines in ovarian physiology and pathol­
ogy as well as role o f the vascular endothelial growth factor 
(VEGF) and antithrombin III (AT III) (1,2). The increased 
capillary permeability and angiogenesis are significant fac­
tors in OHSS pathogenesis (8) (Fig. 1).
VEGF is a homodimeric, heparin-binding glycoprotein 
playing the key role o f mediator in angiogenesis and stimu­
lating vascular permeability. There are two tyrosine kinase 
receptors for VEGF (9) which are produced in theca interna 
and human granulosa cells where two fractions -
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VEGFA 165 and VEGFA 121 predominate (5). AT III is a pro­
tease inhibitor o f clot-activating factors and its deficiency 
may cause thrombosis. One possible way of decreasing AT 
III in patients with severe OHSS is a shift o f albumin in 
extravascular space that may be accompanied by that o f AT 
III because o f its similar molecular weight. 
Thromboembolic incidents can occur in association with 
OHSS and can be observed in patients with hereditary AT 
III deficiency with plasma active levels o f 30-60% o f AT 
III. Acquired AT III deficiency can be suspected with liver 
disease, DIC, nephrotic syndrome, pulmonary embolism, 
stroke and thrombophlebitis. In addition, oral contraceptive 
use may reduce AT III levels (6,10).
The objective o f the present study was to investigate the 
levels o f VEGFA165 and AT III with two patients with 
OHSS and to establish their role in OHSS pathogenesis.
M A T E R IA L  A N D  M E T H O D S
During the period from January, 2003 to January, 2004 in 
IVF Centre o f Varna, two patients with moderate and se­
vere fomi of the OHSS were examined. 1 VF-procedure was 
performed with inhibition o f pituitary gland with 
GnRH-agonist, COH-long protocol - 'step up' depending on 
estradiol levels and follicular development. Exogenous 
gonadotropins were applied in a dose of5000E or 10000E
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Fig. I. Pathogenesis o f  OH SS
HCG (Pregnyl) and aspiration oocytes was done after 
34-36h. On the third day after the punction, three embryos 
were transferred For lutheal support, Utrogestan was ap­
plied. At the start o f the stimulation as well as before appli­
cation o f  HCG, estradiol (E2) and the standard blood pa­
rameters were measured. For establishing the levels of 
VEGF Ai65 in serum, ELISA was used and kits of 
R/D-Sysiems centrifuged at 2000x.g. and stored at -20°C 
were made use of. Plasma AT III levels were measured 
through chromogenic assay kit o f spectrophotometer - 
405nm, centrifuged and stored at -20°C, 30min before use. 
Thrombin reagent, spectrozyme and dilution buffer of 
American Diagnostica Inc. were applied. For establishing 
the control levels o f VEGFA165 and calibration o f AT III 
standards, a control group o f 10 patients was formed who 
participated in IVF-programe - COH with no indication of 
OHSS, liver and hematologic diseases. VEGFAies and AT 
III were measured in serum and plasma. Blood samples for 
VEGF A ,65 and AT III were taken on the second day after 
HCG-application. Referent range for VEGF does not exist, 
therefore, the recommendation o f R/D-Systems is to estab­
lish control levels in the group o f minimum 10 patients.
R E SU L T S A N D  D ISC U SSIO N
With the patient with 'late' OHSS (severe) form, the diagno­
sis was made on the 13th day after the injection o f Pregnyl
5000E and the level o f  E2 before application was 
2,800pg/ml, 10 dominant follicles in the 2 ovaries were 
present. After 36h a punction and aspiration o f 11 oocytes 
o f good quality was realized. ICSI-method was done be­
cause the reason was azoospermia o f  the husband. On the 
3rd day after the punction, embryo transfer o f 3 embryos 
took place. The patient was admitted on the 13th day in our 
hospital in Varna with some complaints such as malaise, 
vomiting, abdominal discomfort, and respiratory distress. It 
was established that ovaries were 4/11cm with theca-luttein 
cysts, large amounts o f ascites were revealed with ultra­
sound examination. OHSS was classified as a severe form 
o f IV grade in reference to clinical and paraclinical parame­
ters. The pregnancy test was positive, later on the ultra­
sound examination showed multiple pregnancy (bigemini) 
which, additionally, exacerbated OHSS. The paracentesis 
was realized with a view to the increased quantity of ascites 
and all therapeutic procedures for treatment o f OHSS. Two 
live twins on the term were bom with Caesarean section in 
38g. w. and their weights were 2,600g and 2,750g, respec­
tively. With the second patient with OHSS the diagnosis 
was established on the 10th day after stimulation with 
gonadothropins. Preventive and therapeutic activities were 
done - 'step down' protocol, coasting HCG, early unilateral 
follicular aspiration, HCG o f 5000E, punction and aspira­
tion o f 14 oocytes, infusion o f human albumin and antibi­
otic treatment. On the 3rd day, embryo transfer o f  2 embryos
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was conducted. The pregnancy was not proved, unfortu­
nately. VEGFA 165 levels o f control group were between 
30-105pg/ml. (67,5pg/ml). The normal laboratory levels of
were normal, VEGFAies - 70 pg/ml and AT III - 95%, re­
spectively. Table 1 shows the laboratory examinations of 
the patient with 'late' OHSS (severe) form.
Table 1. Laboratory indices o f  the patient with severe fo rm  o f  OHSS
Laboratory parameters normal range
Number o f daysafter the diagnosis of OHSS
1 3 6 8 11
hemoglobin 120-160 g/1 175 168 155 130 140
hematocrit 0.36-0.48 0.58 0.52 0.40 0.42 0.42
red blood cells 3.7-5.3*10l2/l 6.2 5.7 5.0 4.4 4.6
leukocytes 3.5-10.5* 109/1 17.0 14.0 10.2 8.9 7.0
platelets 130-360*109/1 380.0 358.0 305.0 309.0 260.0
ESR up to 20mm/h 22mm/h - 17mm/h - 6mm/h
time of bleeding 2 - 5  min 4.7 - 3.0 - -
fibrinogen 2 - 4.5g/l 4.9 4.2 3.9 3.0 4.0
fibrinogen degradation products < 10pg/ml 6.8 13.2 13.8 10.6 8.2
prothrombin time 11.5-15sec 14.5 13.8 15.2 13.2 12.8
activated partial thromboplastin time 28.0-38.0sec 36.0 - 31.0 - -
total protein 60-83g/l 40.1 44.5 58.2 63.3 64.0
ASAT 2-18U/1 20.2 - 14.0 - 6.4
ALAT 2-18U/1 17.2 - 15.8 - 15.2
urea 2.6-7.2mmol 8.8 8.0 7.3 6.3 -
creatinine 58-9.6pmol/l 140 128 109 95 87
K+ 3.5-5.6 mmol/1 5.5 5.1 3.9 4.0 3.6
Na+ 136-151 mmol/1 148 - 140 - -
pH 7.36-7.44 7.42 - 7.40 - -
pOj 10.66-13.33kPa 11.2 10.72 - 11.6 12.0
pC02 4.66-5,99kPa 6.1 5.82 - 4.92 5.2
urine investigation for protein, sugar, ketons, bilirubin, urobilinogen
24h diuresis
E2 before application of HCG - 
2,800ng/ml
AT Ill-second day after HCG 
application - 48%
75-125%
VEGFA 165 - second day after HCG
application - 180mg/ml 
- ■ ■ . ■ — "
Control group 30-105ng/ml
AT III in plasma were 75-125% and o f the control group - 
80-109%. There was an increase o f VEGFAi65 (180 pg/ml) 
and a decrease o f AT III (48%) in the patient with 'late' 
OHSS. These parameters o f the other case with OHSS
Pathogenesis o f  OHSS is still unknown but the increased 
capillary permeability and angiogenesis are primary com­
ponents in it. Some authors report o f OHSS complicated 
with thrombosis without hemoconcentration in a patient
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with AT HI deficiency, as well as of thromboembolic com­
plications after hyperstimulation with hereditary AT III de­
ficiency ( 10). The decrease o f AT III may be a result o f in­
sufficient synthesis, high consumption, abnormal loss due 
to accompanying albumin in extravascular space (6). 
VEGF is the basic inductor o f  cappillary permeability in 
OHSS and the main cause o f ascites, pleural and pericardial 
effusion.
It is suspected that HCG application in the stimulation pro­
tocol causes VEGF synthesis (1). Other researchers con­
sider VEGF a minor clinical marker o f OHSS. It is reported 
that VEGF participates in premature rupture of the mem­
branes. They emphasize its role in the genesis of placental 
hypoxia and its examiantion as a potential early indicator of 
severe birth asphyxia OHSS is classified as 'early' that de­
velops within 3-7 days after ovulatory dose o f HCG and 
'late', after 12-17 days in women with multiple pregnancy. 
The parameters used during the stimulation for prediction 
of OHSS do not show any risk o f development o f  'late' 
OHSS.
There are different opinions about the rate o f E2 for predic­
tion o f OHSS. Some reports show a risk o f 38% for severe 
OHSS with peak o f E2 reaching 6000pg/ml on the day of 
HCG application (9). Their reports which use the same cri­
teria predict only a risk o f 8,8% for development o f severe 
OHSS (7). Some investigators claim that 'late' OHSS does 
not correlate with the peak rate o f E2 like in our case.
C O N C L U SIO N
The measurement o f VEGF rate between the days of HCG 
application and embryo transfer is a possible marker con­
cerning the risk for 'late' OHSS. Our results support in part 
the data published in the literature available about the im­
portance o f VEGF and AT III for OHSS pathogenesis. In 
our opinion, the study should include a larger group o f pa­
tients to measure statistically the real fluctuation of the rates 
o f both factors and their importance for OHSS.
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